SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Street, S. E. A. Articles by Smyth, M. J. Search for Related Content PubMed PubMed Citation Articles by Street, S. E. A. Articles by Smyth, M. J. Related Collections Immunobiology Neoplasia Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 January 2001, Vol. 97, No. 1, pp. 192-197 IMMUNOBIOLOGY Perforin and interferon- activities independently control tumor initiation, growth, and metastasis Shayna E. A. Street, Erika Cretney, and Mark J. Smyth From Cancer Immunology, Peter MacCallum Cancer Institute, Victoria, Australia.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Perforin (pfp) and interferon- (IFN-) together in C57BL/6 (B6) and BALB/c mouse strains provided optimal protection in 3 separate tumor models controlled by innate immunity. Using experimental (B6, RM-1 prostate carcinoma) and spontaneous (BALB/c, DA3 mammary carcinoma) models of metastatic cancer, mice deficient in both pfp and IFN- were significantly less proficient than pfp- or IFN--deficient mice in preventing metastasis of tumor cells to the lung. Pfp and IFN--deficient mice were as susceptible as mice depleted of natural killer (NK) cells in both tumor metastasis models, and IFN- appeared to play an early role in protection from metastasis. Previous experiments in a model of fibrosarcoma induced by the chemical carcinogen methylcholanthrene indicated an important role for NK1.1+ T cells. Herein, both pfp and IFN- played critical and independent roles in providing the host with protection equivalent to that mediated by NK1.1+ T cells. Further analysis demonstrated that IFN-, but not pfp, controlled the growth rate of sarcomas arising in these mice. Thus, this is the first study to demonstrate that host IFN- and direct cytotoxicity mediated by cytotoxic lymphocytes expressing pfp independently contribute antitumor effector functions that together control the initiation, growth, and spread of tumors in mice. (Blood. 2001;97:192-197) © 2001 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Considerable attention has been paid to the direct antitumor activities of cytotoxic lymphocytes within innate and acquired components of the cellular immunity.1 However, until recently, little information was available regarding the relative role of direct cytotoxicity in immunity against tumor development. The development of gene-targeted mice deficient in perforin (pfp)2 and the discovery of several members of the tumor necrosis factor (TNF) superfamily with the capacity to induce tumor cell apoptosis3-5 have paved the way to determining which effector molecules are relevant in tumor immune surveillance. Thus far, in mouse experimental tumor systems, pfp has been demonstrated to protect the host against tumor initiation,6 primary tumor growth,6,7 and tumor metastasis.8 Perforin enables the entry of granzymes that play a key role in target cell DNA fragmentation, but these serine esterases are not critical for tumor cell death mediated by effector cells.9,10 Concerning innate cytotoxicity mediated by NK cells, a role for Fas ligand (FasL) and other TNF family members in tumor immune surveillance is less obvious. Notably, in some models involving innate antitumor activity, natural killer (NK) cell-depleted mice were often significantly more susceptible to tumor metastasis than pfp-deficient mice, despite the lack of activity of FasL or TNF against these tumors in vivo.8 These observations suggested that other pfp-independent effector functions may be contributing to tumor protection. In this light, IFN- is a pleiotropic cytokine that plays a central role in innate and adaptive arms of host immune defense.11,12 IFN- is secreted by NK cells and thymus-derived T cells under certain conditions of activation.13,14 IFN- acts in various ways on host and tumor cells to favor tumor regression, but the relative role that IFN- plays in antitumor responses, compared with direct cytotoxicity by effector molecules such as pfp, has not been previously evaluated. Two studies have elegantly demonstrated a role for IFN- in tumor immune surveillance15,16; however, neither of these determined how important IFN- function was compared with direct cytotoxicity mediated by innate effector cells. Herein, we have undertaken the first study to compare directly the relative role of pfp and IFN- in 3 distinct models of tumor immunity. The 3 tumor models used are distinguished by different relative contributions of NK cells and NK1.1+ T (NKT) cells in host protection. Regardless of the relative role of NK and NKT cells, the creation of mice doubly deficient for pfp and IFN- has demonstrated that these 2 effector arms can act independently and equally effectively yet together account for all the natural antitumor immunity mediated by NK and NKT cells.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Mice Inbred C57BL/6, BALB/c, and BALB/c SCID mice were purchased from The Walter and Eliza Hall Institute of Medical Research (Melbourne, Australia). BALB/c.B6Cmv1r (NK1.1+) were obtained from the Animal Resources Centre (Perth, Australia). The following gene-targeted mice were bred at the Austin Research Institute Biological Research Laboratories (ARI-BRL): C57BL/6.IFN--deficient (B6.IFN-0) (kindly provided by Genentech, San Francisco, CA)17; C57BL/6.perforin-deficient (B6.pfp0) mice2 (from Dr Guna Karupiah, John Curtin School of Medical Research, Canberra, Australia); C57BL/6.IL-12p40-deficient (B6.IL-12p400) mice18 (from Hoffmann-La Roche, Nutley, NJ); C57BL/6.RAG-1-deficient (B6.RAG-10) mice (from Dr Lynn Corcoran, The Walter and Eliza Hall Institute of Medical Research); C57BL/6.T-cell receptor (TCR).J281-deficient (B6.J2810) mice (from Dr Masaru Taniguchi, Chiba University School of Medicine, Chiba, Japan)19; C57BL/6.gld (FasL mutant); BALB/c.perforin-deficient (BALB/c.pfp0),8 and BALB/c.IFN--deficient (BALB/c.IFN-0).17 C57BL/6 and BALB/c mice doubly deficient for perforin and IFN- (B6.pfp0.IFN-0, BALB/c.pfp0.IFN-0) were produced and bred at the ARI-BRL. Mice of 4 to 8 weeks of age were used in all experiments, performed according to animal experimental ethics committee guidelines. Cell culture and chromium 51Cr release assays The mouse tumor cell lines and spleen cell cultures used in this study were maintained as previously described.8,19,20 Cytotoxicity of freshly isolated mouse spleen cells or IL-2-activated adherent NK cells (greater than 80% NK1.1+ TCR) from wild-type or gene-targeted mice were assessed by 4-hour chromium 51Cr release assays against labeled targets as described.7 Each experiment was performed twice with at least 4 different effector-target ratios using duplicate samples. Subset depletion The protocols for depletion of NK1.1+ (NK and NKT) cells in B6 mice using anti-NK1.1 monoclonal antibody (mAb) (PK136) were as previously described.8,19 Groups of BALB/c and BALB/c.B6Cmv1r (NK1.1+) mice were depleted of asialo GM1+ cells using the rabbit anti-asialo GM1 antibody (Wako Chemicals, Richmond, VA) as described.8 The BALB/c.B6Cmv1r (NK1.1+) mice were used to show that this depletion was effective because DX5 and other markers are not entirely suitable for detecting NKT cells. Anti-asialo GM1 antibody depleted NK1.1+ TCR NK cells, but not NK1.1+TCR+ NK) T cells (Table 1). Assessment of depletion was performed after the preparation of cell suspensions from spleen and liver as described.21 Flow cytometry of cells was performed with allophycocyanin-conjugated anti-TCR (clone H57-597) and phycoerythrin-conjugated anti-NK1.1, purchased from Pharmingen (San Diego, CA).                                View this table: [in this window] [in a new window]   Table 1. Depletion of NK cells using anti-asialo GM1 antibody in BALB/c.B6Cmv1r mice Tumor surveillance in vivo Effector function was examined in 3 different tumor models (RM-1, DA3, and methylcholanthrene [MCA] induction of fibrosarcoma), as described, using gene-targeted mice or mice depleted of lymphocyte subsets.8,19 In the RM-1 model, mice were injected subcutaneously with RM-1 tumor cells (2 × 106), and tumors were established for 9 days. At this time, subcutaneous tumors were surgically resected, and fresh in vitro cultured RM-1 cells were injected through the dorsolateral tail vein. Mice were killed 14 days later, the lungs were removed and fixed in Bouin's solution, and surface lung metastases were counted blinded with the aid of a dissecting microscope. Additionally, in the RM-1 tumor model, groups of B6 mice were treated with rat antimouse IFN- mAb (R4-6A2) or control rat IgG1 (R3-34; Pharmingen, San Diego, CA) (500 µg each) on days 2, 0 (day of intravenous tumor inoculation), 2, 7, and 10. Some mice received anti-mIFN- mAb early (days 2, 0) and others late (days 7, 10). Protocols that have used similar concentrations and conditions have been shown to effectively inhibit mIFN- activity in vivo.22 Data were recorded as the mean number of metastases ± SEM. Significance was determined by a Mann-Whitney U (rank sum) test.     Results Top Abstract Introduction Materials and methods Results Discussion References NK and NKT cell number and NK cytotoxic function in gene-targeted mice Multiparameter flow cytometry was used to examine the status of NK and NKT cells in the various mouse strains in this study. To use the NK1.1 marker, B6 strains were examined. Cell suspensions were made from thymus, spleen, liver, bone marrow, lymph nodes, and peritoneal exudate cells. As expected, NK1.1+ cells were detected in each organ and included both TCR (NK cells) and TCR+ (NKT cells). Both NK and NKT cells were clearly present in the appropriate organs of wild-type, B6.IFN-0, B6.pfp0, and B6.pfp0.IFN-0 strains (data not shown). Next, the cytotoxic function of NK cells in both B6 and BALB/c gene-targeted mice was examined in a 4-hour 51Cr release assay against class 1-deficient, NK-sensitive targets (RMA-S and DA3) and class 1-expressing targets (RMA and P815) (Figure 1A-B). In both strains (B6 and BALB/c), freshly isolated splenocytes or IL-2-activated adherent NK cells (greater than 80%) from the spleen of wild-type or IFN-0 mice displayed NK and LAK activity (Figure 1A-B). By contrast, resting or IL-2-activated adherent NK cells from the spleen of pfp0 or pfp0.IFN-0 mice displayed little or no NK and LAK activity (Figure 1A-B). These data confirmed that pfp, but not IFN-, was critical for direct cytotoxicity by NK cells. View larger version (28K): [in this window] [in a new window]   Figure 1. NK-cell-mediated cytotoxicity of pfp and IFN- gene-targeted mice. Resting splenocytes and IL-2-activated adherent spleen NK cells were assessed by 4-hour 51Cr release assays using labeled targets as indicated for (A) B6 or (B) BALB/c strains of mice. An effector-target ratio of 100:1 is shown (4 were examined). The spontaneous release of 51Cr was always less than 15% (subtracted from test), and each experiment was performed twice using triplicate samples. NK cell-mediated control of spontaneous metastasis by independent pfp and IFN- activities The relative importance of pfp and IFN- was next examined in a model of spontaneous metastasis that is strictly controlled by NK cells.8 Two different DA3 tumor doses (105 and 5 × 105) were inoculated subcutaneously, and after 42 days, lung metastases were counted. There were significantly increased numbers of metastases in BALB/c.pfp0 mice or BALB/c.IFN-0 mice compared with wild-type BALB/c mice, but fewer than found in NK cell-depleted (anti-asialo GM1-treated) mice (Figure 2). Anti-asialo GM1 antibody depletion was complete and specific for NK cells and did not effectively deplete NKT- or T-cell populations (Table 1). Similar increases in DA3 lung metastasis were observed in BALB/c.B6Cmv1r mice depleted with anti-asialo GM1 antibody (Figure 2 legend). There was no increase in DA3 metastases in T-cell- and NKT-cell-deficient BALB/c.SCID mice (Figure 2). Importantly, BALB/c.pfp0.IFN-0 mice were as susceptible to tumor metastasis as NK-cell-depleted mice. In addition, qualitatively equivalent results were obtained in mice simply injected intravenously with DA3 tumor cells (data not shown), suggesting that pfp and IFN- were both protecting against tumor cell engraftment in the lung rather than migration from the subcutaneous site of inoculation. View larger version (57K): [in this window] [in a new window]   Figure 2. NK-cell-mediated control of spontaneous metastasis by independent pfp and IFN- activities. BALB/c, BALB/c.SCID, BALB/c.IFN-0, BALB/c.pfp0, and BALB/c pfp0.IFN-0 mice or BALB/c mice treated with anti-asialo GM1 antibody (100 µg/injection) were inoculated subcutaneously with DA3 tumor cells (105 or 5 × 105) as indicated. Mice depleted of subsets in vivo were treated on days 4, 0 (day of subcutaneous tumor inoculation), and weekly thereafter. Forty-two days after tumor inoculation, the lungs of these mice were harvested and fixed, and colonies were counted and recorded as the mean number of colonies ± SE. Asterisks indicate the groups that are significantly different from BALB/c-untreated mice (*P < .0001; **P < .005; Mann-Whitney U test). A significant difference was also detected between the BALB/c.P0 mice or BALB/c.IFN-0 mice and BALB/cP0.IFN-0 mice (P < .0001). The number of mice per group is shown in parentheses. Note that for groups of 5 mice receiving 105 DA3 tumor cells, the numbers of DA3 lung colonies were as follows: BALB/c.B6Cmv1r = 8.0 ± 2.6; BALB/c.B6Cmv1r + anti-asialo GM1 antibody = 62.4 ± 6.6. NK- and NKT-cell-mediated control of experimental tumor metastasis by independent pfp and IFN- activities Innate protection from metastasis was then examined in the B6 RM-1 tumor model in which NK and NKT cells have previously been shown to control tumor metastasis.8,19 Confirming previous reports, B6 mice depleted of NK1.1+ cells displayed a significantly higher number of RM-1 lung metastases than B6 mice deficient for T cells and NKT cells (RAG-10) or NKT cells alone (J2810) (Figure 3A). These data suggested that NK cells were the primary effector population, but clearly NKT cells play some role in RM-1 tumor protection because J2810 mice displayed significantly more metastases than untreated B6 mice. The major effector molecules involved in host protection were pfp, IL-12, and IFN-, as evidenced by the significant increase in RM-1 lung metastases in mice deficient for each of these molecules (Figure 3A). Nevertheless, B6.pfp0, B6.IL-12p400, and B6.IFN-0 mice had significantly fewer RM-1 lung colonies than B6 mice depleted of NK1.1+ cells (Figure 3A). In this model, we have already demonstrated that B6.pfp0 mice or B6.IFN-0 mice treated with anti-NK1.1 mAb do not develop more metastases than B6 mice treated with anti-NK1.1 mAb; thus, pfp and IFN- activities are not independent of NK cell function.23 Although IFN- can clearly potentiate the apoptotic activity of TNF superfamily molecules,12 including TNF-related, apoptosis-inducing ligand24 (not assessed herein), no apparent role for FasL or TNF effector molecules was observed in this model of metastases (Figure 3A). View larger version (33K): [in this window] [in a new window]   Figure 3. NK- and NKT-cell-mediated control of experimental tumor metastasis by independent pfp and IFN- activities. (A) B6, B6.pfp0, B6.RAG-10, B6.TNF0, B6.IFN-0, and B6.gld mice or B6 mice treated with anti-NK1.1 were inoculated subcutaneously between the shoulder blades with RM-1 tumor cells (2 × 106), and tumors were allowed to establish for 9 days. Subcutaneous tumors were then resected and a dose range of RM-1 cells (as indicated) injected through the tail vein. Mice were killed 14 days later, the lungs were removed and fixed, and colonies were counted and recorded as the mean number of colonies ± SE. A group of B6 mice was depleted of NK1.1+ cells in vivo by mAb treatment (100 µg/injection) on days 2, 0 (day of intravenous tumor inoculation), 2, and 9. (B) B6, B6.pfp0, B6.IFN-0, and B6.pfp0.IFN-0 mice or B6 and B6.pfp0 mice treated with anti-mIFN- mAb (500 µg/injection) or control mAb (500 µg/injection) were treated as above. Mice received anti-IFN- mAb on days 2, 0 (day of intravenous tumor inoculation), 2, 7, and 10, with some groups receiving anti-mIFN- mAb early (days 2, 0) or late (days 7, 10). (A) Significant differences from the B6 group were determined by a Mann-Whitney U test (*P < .0001). Additionally, mice treated with anti-NK1.1 had significantly more metastases than any other group, including B6.pfp0 and B6.IFN-0 mice (P < .0001). (B) Significant differences from the B6.pfp0 group were determined by a Mann-Whitney U test and denoted (*P < .0001). The number of mice per group is shown in parentheses. To evaluate whether the effector functions of pfp, IL-12, and IFN- were independent or overlapping, B6, B6.J2810, B6.IL-12p400, or B6.pfp0 mice were treated with neutralizing antimouse IFN- mAb over the course of the challenge with RM-1 tumor cells. Anti-IFN- mAb significantly increased the incidence of lung metastasis in both B6 and B6.pfp0 mice, but only minor increases were observed in B6.J2810 or B6.IL-12p400 mice (Figure 3B). The effect was most prominent when mAb was administered early, rather than late, after the tumor challenge. The enhanced number of RM-1 lung metastases in B6.pfp0 mice treated with anti-IFN- was further supported by the number of metastases in B6.pfp0.IFN-0 mice. When directly compared (ie, same experiments), the B6.pfp0.IFN-0 mice displayed tumor incidence equivalent to B6 mice depleted of NK1.1+ cells (Figure 3B compared with Figure 3A). NKT cells have recently been demonstrated to rapidly activate NK cells by their production of IFN-.25 The early protective effect of anti-IFN- mAb in the RM-1 tumor model may also support this concept. Nonetheless, the greater defect observed in mice depleted of all NK1.1+ cells suggested that NK cells have protective mechanisms independent of NKT cells. The results in mice deficient for pfp, or pfp and IFN-, indicated this independent antimetastatic function of NK cells may involve both the cytolytic activity of pfp and antitumor activity of IFN-. Therefore, these data in the RM-1 tumor model supported our previous results in the DA3 tumor modelthat innate effector cells protected the host from lung metastases and that pfp and IFN- were independent effector mechanisms that contributed to protection. NKT-cell-mediated control of MCA-induced fibrosarcoma by independent pfp and IFN- activities Induction of fibrosarcoma by MCA has previously been demonstrated to be controlled by effector cells in a pfp-dependent and an IFN- receptor-dependent manner.2,16,19 By examining the relative deficiencies of B6 mice depleted of NK1.1+ cells and B6 mice specifically deficient in V14 TCR NK1.1+ T cells (J2810), we have been able to establish that these NKT cells play a major role in protection from MCA-induced sarcoma.19 Herein we created B6 mice doubly deficient for pfp and IFN-. Groups of B6 and B6 gene-targeted mice were injected subcutaneously with 2 different doses of MCA, and fibrosarcoma development was monitored for 180 days (Figure 4A). At the doses examined, B6.pfp0 mice and B6.IFN-0 mice developed tumors significantly more frequently than B6 control mice. These data in B6 mice confirmed a role for pfp6,8 and IFN-,16 previously suggested by studies in this strain. In addition, at the 2 doses examined, a greater proportion (90% and 80%) of B6.pfp0.IFN-0 mice succumbed to MCA-induced sarcoma than either B6.pfp0 mice or B6.IFN-0 mice (Figure 4A). The B6.pfp0.IFN-0 mice displayed a similar sarcoma incidence to NKT-cell-deficient B6.J2810 mice (Figure 4A). Thus, in a third model involving innate protection from tumor initiation, the combined deficiency of pfp and IFN- compromised the host to a greater extent than loss of pfp or IFN- alone. A random group of 10 mice was monitored for individual tumor growth in groups receiving 100 µg MCA (Figure 4B) or 25 µg MCA (data not shown). Strikingly, the growth of sarcomas in B6.IFN-0, B6.pfp0.IFN-0, or B6.J2810 mice was significantly greater than that compared with B6 or B6.pfp0 mice. This increase in the growth rate of sarcomas in IFN--deficient mice occurred despite similar rates of incidence between B6.pfp0 and B6.IFN-0 mice (Figure 4A). Similar data have been obtained in the same BALB/c strains of mice treated with MCA (data not shown). Therefore, though IFN- was important in the control of sarcoma initiation, it appears that IFN- and NKT cells were also very important in the control of sarcoma growth. View larger version (17K): [in this window] [in a new window]   Figure 4. NKT-cell-mediated control of MCA-induced fibrosarcoma by independent pfp and IFN- activities. (A) Groups of 10 to 43 B6, B6.J2810, B6.pfp0, B6.IFN-0, or B6 pfp0.IFN-0 mice were injected subcutaneously in the hind flank with 100 µg or 25 µg MCA diluted in 0.1 mL corn oil. Mice were observed weekly for tumor development over the course of 50 to 180 days. Tumors larger than 4 mm in diameter and demonstrating progressive growth over 3 weeks were counted as positive. Groups with statistically higher incidence than B6 mice were noted (*P < .01; **P < .05; Fisher exact test). (B) Representative individual fibrosarcomas from groups of 10 mice (above) were compared with a group of B6 mice receiving 400 µg MCA. Tumor size was measured daily with a caliper square as the product of 2 diameters, and results were recorded as the tumor size (cm2). The mean growth rate of tumors was determined from the gradients of individual plots and was normalized against the mean of the B6 (400 µg) group = 1.0. Data are plotted as the mean ± SE, and significant differences to the B6 (400 µg) control were determined by an unpaired t test with Welch correction (*P < .01)     Discussion Top Abstract Introduction Materials and methods Results Discussion References In 3 distinct models of tumor initiation and metastasis, the sensitivity of mice deficient in pfp and IFN- indicated that both effector mechanisms independently contribute to innate tumor immunity mediated by NK1.1+ NK or NK1.1+ T cells. For some time it has been recognized that IFN- production and pfp-mediated cytotoxicity may be distinct events that contribute to innate immunity. In particular, in viral infection, IL-12 is required for NK cell IFN- production but not cytotoxicity, whereas IFN-/ production is dominant for enhanced NK lytic activity.26 In T-cell-mediated responses, a critical balance exists between direct cytotoxicity mediated by pfp and IFN- secretion that determines the outcome of viral infection and dictates immune homeostasis.27,28 In tumor models, each of pfp and IFN- have been demonstrated to contribute to the control of tumor incidence and metastasis,6-8,15,16,19,23,29,30 but no previous studies have directly compared their relative activities in the same model or examined the effect of removing both activities. Herein, in innate antitumor responses that involve relatively different contributions by NK and NKT cells, we have demonstrated for the first time that the killer cell pfp and cytokine IFN- constitute independent mechanisms that together control tumor initiation and metastasis. The critical role of pfp in the direct cytolysis of tumor cells by NK cells is undisputed2; however, the mechanism(s) of IFN- action may be more diverse,12,31-36 and exactly which function is most important remains controversial. Although originally defined as an agent with direct antiviral activity,37 IFN- regulates several aspects of the immune response, including the stimulation of antigen presentation by up-regulation of major histocompatability complex (MHC) class I and II molecules,12 the orchestration of leukocyte-endothelium interactions,12,31 the effects on cell proliferation32 and sensitivity to apoptosis,33,34 the stimulation of the bactericidal activity of phagocytes,12 and anti-angiogenesis.35,36 A recent study has also indicated that IFN- may contribute directly to pfp-mediated apoptosis by altering target cell sensitivity.38 From this and many other studies, it is clear the roles of IFN- in host responses to tumor are complex, and it will not be easy to dissect the relative role of these molecules in destroying tumors, activating innate cells, or inhibiting tumor angiogenesis. Much of the reason for the controversies about which IFN- function is most important is the great variety of settings in which IFN- has been studied. We chose to focus on tumor models involving several different host innate responses, with the knowledge that each tumor may be controlled by a unique combination of NK/NKT cell mechanisms. Although our study has not contributed greatly to our knowledge of how IFN- may control tumors, in at least one model (DA3), the enhancement of tumor immunogenicity by IFN- up-regulation of MHC class I and II molecules seems unlikely given that T cells played no part in host protection from tumor metastasis. One outstanding feature of tumor behavior in mice deficient for IFN- was the increased growth rate of MCA-induced sarcomas. The fact that NKT-cell-deficient mice, but not pfp-deficient mice, also demonstrated increased sarcoma growth further suggested that IFN- may be an important feature of the NKT-cell response. The effect of IFN- was distinct from that observed in a study comparing IFN--responsive and -unresponsive mammary carcinomas that enlarged at similar rates.35 However, we (Smyth, unpublished data) and others15,29 have observed that IFN- is an important molecule in the control of tumor growth in other models. The mechanism by which IFN- controls sarcoma tumor growth remains unknown, but we did note that in vitro stimulation of cell lines derived from MCA-induced tumors with IFN- did not reveal any decrease in proliferation (data not shown). Additional combinations of cytokines may be required to determine whether any combination can suppress tumor cell proliferation. The possibility that IFN- has anti-angiogenic activity is also being explored; however, previous data using the MCA tumor model suggested that the key targets of the action of IFN- were the tumor cells themselves.16 IFN- may also have been controlling tumor growth in the RM-1 and DA3 metastasis models. Thus, in the absence of an assay to measure micrometastases for these experimental tumors, it is possible that numbers of surface lung tumor colonies measured at defined points in time may have underestimated tumor burden in wild-type and B6.pfp0 mice. In summary, we have used the most rigorous and specific means available to distinguish the relative roles of NK and NKT cells in their control of tumor initiation, metastasis, and growth. Regardless of the varying relative roles of NK and NKT cells in each of the models used, host pfp and IFN- were consistently demonstrated to contribute independently to tumor control. Future efforts will focus on defining how pfp-independent NK/NKT-cell antitumor functions are orchestrated by IFN-.     Acknowledgment We thank the staff of the ARI-BRL for their maintenance and care of the mice in this project.     Footnotes Submitted May 17, 2000; accepted July 28, 2000. Supported by a National Health and Medical Research Council (NHMRC) of Australia project grant. M.J.S. is supported by an NHMRC Principal Research Fellowship. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Mark J. Smyth, Cancer Immunology, Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, Victoria, Australia, 8006; e-mail: m.smyth{at}pmci.unimelb.edu.au.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Alexandroff AB, McIntyre CA, Porter JC, Zeuthen J, Vile RG, Taub DD. Sticky and smelly issues: lessons on tumour cell and leucocyte trafficking, gene and immunotherapy of cancer. Br J Cancer 1998;77:1806-1811[Medline] [Order article via Infotrieve]. 2. Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994;369:31-37[CrossRef][Medline] [Order article via Infotrieve]. 3. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255-260[CrossRef][Medline] [Order article via Infotrieve]. 4. Depraetere V, Golstein P. Fas and other cell death signaling pathways. Semin Immunol. 1997;9:93-107[CrossRef][Medline] [Order article via Infotrieve]. 5. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365[CrossRef][Medline] [Order article via Infotrieve]. 6. van den Broek ME, Kagi D, Ossendorp F, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996;184:1781-1790[Abstract/Free Full Text]. 7. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med. 1998;188:1611-1619[Abstract/Free Full Text]. 8. Smyth MJ, Thia KY, Cretney E, et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol. 1999;162:6658-6662[Abstract/Free Full Text]. 9. Trapani JA, Sutton VR, Smyth MJ. CTL granules: evolution of vesicles essential for combating virus infections. Immunol Today. 1999;20:351-356[CrossRef][Medline] [Order article via Infotrieve]. 10. Simon MM, Hausmann M, Tran T, et al. In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A × B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. J Exp Med. 1997;186:1781-1786[Abstract/Free Full Text]. 11. Farrar MA, Schreiber RD. The molecular cell biology of interferon- and its receptor. Annu Rev Immunol. 1993;11:571-611[CrossRef][Medline] [Order article via Infotrieve]. 12. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-. Annu Rev Immunol. 1997;15:749-795[CrossRef][Medline] [Order article via Infotrieve]. 13. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol. 1994;12:635-673[CrossRef][Medline] [Order article via Infotrieve]. 14. Trinchieri G. Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol. 1995;7:83-88[CrossRef][Medline] [Order article via Infotrieve]. 15. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN- receptors. Immunity. 1994;1:447-456[CrossRef][Medline] [Order article via Infotrieve]. 16. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon -dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998;95:7556-7561[Abstract/Free Full Text]. 17. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon- genes. Science. 1993;259:1739-1742[Abstract/Free Full Text]. 18. Magram J, Connaughton SE, Warrier WW, et al. IL-12 deficient mice are defective in IFN- production and type 1 cytokine responses. Immunity. 1996;4:471-481[CrossRef][Medline] [Order article via Infotrieve]. 19. Smyth MJ, Thia KYT, Street SEA, et al. Differential tumor surveillance by NK and NKT cells. J Exp Med. 2000;191:661-668[Abstract/Free Full Text]. 20. Smyth MJ, Kershaw MH, Trapani JA. Xenospecific cytotoxic T lymphocytes: potent lysis in vitro and in vivo. Transplantation. 1997;63:1171-1178[CrossRef][Medline] [Order article via Infotrieve]. 21. Hammond K, Cain W, van Driel I, Godfrey D. Three day neonatal thymectomy selectively depletes NK1.1+ T cells. Int Immunol. 1998;10:1491-1499[Abstract/Free Full Text]. 22. Sarawar S, Sangster RM, Coffman RL, Doherty PC. Administration of anti-IFN- antibody to b2-microglobulin-deficient mice delays influenza virus clearance but does not switch the response to a T helper cell 2 phenotype. J Immunol. 1994;153:1246-1253[Abstract]. 23. Smyth MJ, Snook MB. Perforin-dependent cytolytic responses in 2-microglobulin-deficient mice. Cell Immunol. 1999;196:51-59[CrossRef][Medline] [Order article via Infotrieve]. 24. Sedger LM, Shows DM, Blanton RA, et al. IFN- mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol. 1999;163:920-926[Abstract/Free Full Text]. 25. Carnaud C, Lee D, Donnars O, et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol. 1999;163:4647-4650[Abstract/Free Full Text]. 26. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189-220[CrossRef][Medline] [Order article via Infotrieve]. 27. Nansen A, Jensen T, Christiansen JP, Ropke SO, Marker O, Thomsen AR. Compromised virus control and augmented perforin-mediated immunopathology in IFN--deficient mice infected with lymphochoriomeningitis virus. J Immunol. 1999;163:6114-6122[Abstract/Free Full Text]. 28. Slifka MK, Rodriguez F, Whitton JL. Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells. Nature. 1999;401:76-79[CrossRef][Medline] [Order article via Infotrieve]. 29. Lee JK, Sayers TJ, Brooks AD, et al. IFN-- dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol. 2000;164:231-239[Abstract/Free Full Text]. 30. Kawamura T, Takeda K, Mendiratta SK, et al. Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol. 1998;160:16-19[Abstract/Free Full Text]. 31. Billiau A, Heremans H, Vermeire K, Matthys P. Immunomodulatory properties of interferon-: an update. Ann N Y Acad Sci. 1998;856:22-32[CrossRef][Medline] [Order article via Infotrieve]. 32. Hawley RG, Berger LC. Growth control mechanisms in multiple myeloma. Leuk Lymphoma. 1998;29:465-475[Medline] [Order article via Infotrieve]. 33. Tamura T, Ishihara M, Lamphier MS, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature. 1995;376:596-599[CrossRef][Medline] [Order article via Infotrieve]. 34. Dai C, Krantz SB. Interferon- induces up-regulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood. 1999;93:3309-3316[Abstract/Free Full Text]. 35. Coughlin CM, Salhany KE, Gee MS, et al. Tumor cell responses to IFN affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity. 1998;9:25-34[CrossRef][Medline] [Order article via Infotrieve]. 36. Yao L, Sgadari C, Furuke F, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood. 1999;93:1612-1621[Abstract/Free Full Text]. 37. Hovanessian AG. Interferon-induced dsRNA-activated protein kinase (PKR): antiproliferative, antiviral and antitumoral functions. Semin Virol. 1993;4:237-245[CrossRef]. 38. Berthou C, Bourge JF, Zhang Y, et al. Interferon--induced membrane PAF-receptor expression confers tumor cell susceptibility to NK perforin-dependent lysis. Blood. 2000;95:2329-2336[Abstract/Free Full Text]. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Clarification of data used in three studies on MCA-induction of sarcoma in mice Mark J. Smyth Blood 2008 111: 4419. [Full Text] [PDF] This article has been cited by other articles: S. A. Broomfield, R. G. van der Most, A. C. Prosser, S. Mahendran, M. G. Tovey, M. J. Smyth, B. W. S. Robinson, and A. J. Currie Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy J. Immunol., May 1, 2009; 182(9): 5217 - 5224. [Abstract] [Full Text] [PDF] P. Bolitho, S. E. A. Street, J. A. Westwood, W. Edelmann, D. MacGregor, P. Waring, W. K. Murray, D. I. Godfrey, J. A. Trapani, R. W. Johnstone, et al. Perforin-mediated suppression of B-cell lymphoma PNAS, February 24, 2009; 106(8): 2723 - 2728. [Abstract] [Full Text] [PDF] M. B. F. Werneck, G. Lugo-Villarino, E. S. Hwang, H. Cantor, and L. H. Glimcher T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease J. Immunol., June 15, 2008; 180(12): 8004 - 8010. [Abstract] [Full Text] [PDF] C. Hastie, J. R. Masters, S. E. Moss, and S. Naaby-Hansen Interferon-{gamma} Reduces Cell Surface Expression of Annexin 2 and Suppresses the Invasive Capacity of Prostate Cancer Cells J. Biol. Chem., May 2, 2008; 283(18): 12595 - 12603. [Abstract] [Full Text] [PDF] M. J. Smyth, M. W.L. Teng, J. Sharkey, J. A. Westwood, N. M. Haynes, H. Yagita, K. Takeda, P. V. Sivakumar, and M. H. Kershaw Interleukin 21 Enhances Antibody-Mediated Tumor Rejection Cancer Res., April 15, 2008; 68(8): 3019 - 3025. [Abstract] [Full Text] [PDF] M. J. Smyth Clarification of data used in three studies on MCA-induction of sarcoma in mice Blood, April 15, 2008; 111(8): 4419 - 4419. [Full Text] [PDF] J. B. Swann, M. D. Vesely, A. Silva, J. Sharkey, S. Akira, R. D. Schreiber, and M. J. Smyth Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis PNAS, January 15, 2008; 105(2): 652 - 656. [Abstract] [Full Text] [PDF] K. S. Bahjat, R. A. Prell, H. E. Allen, W. Liu, E. E. Lemmens, M. L. Leong, D. A. Portnoy, T. W. Dubensky Jr., D. G. Brockstedt, and M. A. Giedlin Activation of Immature Hepatic NK Cells As Immunotherapy for Liver Metastatic Disease J. Immunol., December 1, 2007; 179(11): 7376 - 7384. [Abstract] [Full Text] [PDF] D. Wu, M. Pae, Z. Ren, Z. Guo, D. Smith, and S. N. Meydani Dietary Supplementation with White Button Mushroom Enhances Natural Killer Cell Activity in C57BL/6 Mice J. Nutr., June 1, 2007; 137(6): 1472 - 1477. [Abstract] [Full Text] [PDF] D. S. Dace, P. W. Chen, and J. Y. Niederkorn CD8+ T Cells Circumvent Immune Privilege in the Eye and Mediate Intraocular Tumor Rejection by a TNF-{alpha}-Dependent Mechanism J. Immunol., May 15, 2007; 178(10): 6115 - 6122. [Abstract] [Full Text] [PDF] J. J. Subleski, V. L. Hall, T. C. Back, J. R. Ortaldo, and R. H. Wiltrout Enhanced Antitumor Response by Divergent Modulation of Natural Killer and Natural Killer T Cells in the Liver. Cancer Res., November 15, 2006; 66(22): 11005 - 11012. [Abstract] [Full Text] [PDF] U. I. Chaudhry, T. P. Kingham, G. Plitas, S. C. Katz, J. R. Raab, and R. P. DeMatteo Combined Stimulation with Interleukin-18 and CpG Induces Murine Natural Killer Dendritic Cells to Produce IFN-{gamma} and Inhibit Tumor Growth Cancer Res., November 1, 2006; 66(21): 10497 - 10504. [Abstract] [Full Text] [PDF] C. Lamagna, M. Aurrand-Lions, and B. A. Imhof Dual role of macrophages in tumor growth and angiogenesis J. Leukoc. Biol., October 1, 2006; 80(4): 705 - 713. [Abstract] [Full Text] [PDF] K. Abdool, E. Cretney, A. D. Brooks, J. M. Kelly, J. Swann, A. Shanker, E. W. Bere Jr., W. M. Yokoyama, J. R. Ortaldo, M. J. Smyth, et al. NK Cells Use NKG2D to Recognize a Mouse Renal Cancer (Renca), yet Require Intercellular Adhesion Molecule-1 Expression on the Tumor Cells for Optimal Perforin-Dependent Effector Function J. Immunol., August 15, 2006; 177(4): 2575 - 2583. [Abstract] [Full Text] [PDF] P. Juszczynski, J. L. Kutok, C. Li, J. Mitra, R. C. T. Aguiar, and M. A. Shipp BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate. Mol. Cell. Biol., July 1, 2006; 26(14): 5348 - 5359. [Abstract] [Full Text] [PDF] N. Papo, D. Seger, A. Makovitzki, V. Kalchenko, Z. Eshhar, H. Degani, and Y. Shai Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic Peptide. Cancer Res., May 15, 2006; 66(10): 5371 - 5378. [Abstract] [Full Text] [PDF] Y. Gao, J. Tao, M. O. Li, D. Zhang, H. Chi, O. Henegariu, S. M. Kaech, R. J. Davis, R. A. Flavell, and Z. Yin JNK1 Is Essential for CD8+ T Cell-Mediated Tumor Immune Surveillance J. Immunol., November 1, 2005; 175(9): 5783 - 5789. [Abstract] [Full Text] [PDF] S. Dasgupta, M. Bhattacharya-Chatterjee, B. W. O'Malley Jr, and S. K. Chatterjee Inhibition of NK Cell Activity through TGF-{beta}1 by Down-Regulation of NKG2D in a Murine Model of Head and Neck Cancer J. Immunol., October 15, 2005; 175(8): 5541 - 5550. [Abstract] [Full Text] [PDF] H. Nishikawa, T. Kato, I. Tawara, T. Takemitsu, K. Saito, L. Wang, Y. Ikarashi, H. Wakasugi, T. Nakayama, M. Taniguchi, et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts PNAS, June 28, 2005; 102(26): 9253 - 9257. [Abstract] [Full Text] [PDF] M. J. Smyth, M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey, and Y. Hayakawa Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer J. Exp. Med., June 20, 2005; 201(12): 1973 - 1985. [Abstract] [Full Text] [PDF] A. Arjona and D. K. Sarkar Circadian Oscillations of Clock Genes, Cytolytic Factors, and Cytokines in Rat NK Cells J. Immunol., June 15, 2005; 174(12): 7618 - 7624. [Abstract] [Full Text] [PDF] K. Liu, S. A. Caldwell, and S. I. Abrams Immune Selection and Emergence of Aggressive Tumor Variants as Negative Consequences of Fas-Mediated Cytotoxicity and Altered IFN-{gamma}-Regulated Gene Expression Cancer Res., May 15, 2005; 65(10): 4376 - 4388. [Abstract] [Full Text] [PDF] G. P. Dunn, K. C.F. Sheehan, L. J. Old, and R. D. Schreiber IFN Unresponsiveness in LNCaP Cells Due to the Lack of JAK1 Gene Expression Cancer Res., April 15, 2005; 65(8): 3447 - 3453. [Abstract] [Full Text] [PDF] V. Milani, B. Frankenberger, O. Heinz, A. Brandl, S. Ruhland, R. D. Issels, and E. Noessner Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response Int. Immunol., March 1, 2005; 17(3): 257 - 268. [Abstract] [Full Text] [PDF] X.-W. Liu, M. E. Taube, K.-K. Jung, Z. Dong, Y. J. Lee, S. Roshy, B. F. Sloane, R. Fridman, and H.-R. C. Kim Tissue Inhibitor of Metalloproteinase-1 Protects Human Breast Epithelial Cells from Extrinsic Cell Death: A Potential Oncogenic Activity of Tissue Inhibitor of Metalloproteinase-1 Cancer Res., February 1, 2005; 65(3): 898 - 906. [Abstract] [Full Text] [PDF] I. Voskoboinik, M.-C. Thia, A. De Bono, K. Browne, E. Cretney, J. T. Jackson, P. K. Darcy, S. M. Jane, M. J. Smyth, and J. A. Trapani The Functional Basis for Hemophagocytic Lymphohistiocytosis in a Patient with Co-inherited Missense Mutations in the Perforin (PFN1) Gene J. Exp. Med., September 20, 2004; 200(6): 811 - 816. [Abstract] [Full Text] [PDF] K. Takeda and K. Okumura CAM and NK Cells Evid. Based Complement. Altern. Med., June 1, 2004; 1(1): 17 - 27. [Abstract] [Full Text] [PDF] S. E.A. Street, Y. Hayakawa, Y. Zhan, A. M. Lew, D. MacGregor, A. M. Jamieson, A. Diefenbach, H. Yagita, D. I. Godfrey, and M. J. Smyth Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and {gamma}{delta} T Cells J. Exp. Med., March 15, 2004; 199(6): 879 - 884. [Abstract] [Full Text] [PDF] Y. Hayakawa, V. Screpanti, H. Yagita, A. Grandien, H.-G. Ljunggren, M. J. Smyth, and B. J. Chambers NK Cell TRAIL Eliminates Immature Dendritic Cells In Vivo and Limits Dendritic Cell Vaccination Efficacy J. Immunol., January 1, 2004; 172(1): 123 - 129. [Abstract] [Full Text] [PDF] Y. Hayakawa, S. Rovero, G. Forni, and M. J. Smyth {alpha}-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis PNAS, August 5, 2003; 100(16): 9464 - 9469. [Abstract] [Full Text] [PDF] Y. Gao, W. Yang, M. Pan, E. Scully, M. Girardi, L. H. Augenlicht, J. Craft, and Z. Yin {gamma}{delta} T Cells Provide an Early Source of Interferon {gamma} in Tumor Immunity J. Exp. Med., August 4, 2003; 198(3): 433 - 442. [Abstract] [Full Text] [PDF] H. J. J. van der Vliet, J. W. Molling, N. Nishi, A. J. Masterson, W. Kolgen, S. A. Porcelli, A. J. M. van den Eertwegh, B. M. E. von Blomberg, H. M. Pinedo, G. Giaccone, et al. Polarization of V{alpha}24+ V{beta}11+ Natural Killer T Cells of Healthy Volunteers and Cancer Patients Using {alpha}-Galactosylceramide-loaded and Environmentally Instructed Dendritic Cells Cancer Res., July 15, 2003; 63(14): 4101 - 4106. [Abstract] [Full Text] [PDF] M. J. Smyth, S. E. A. Street, and J. A. Trapani Cutting Edge: Granzymes A and B Are Not Essential for Perforin-Mediated Tumor Rejection J. Immunol., July 15, 2003; 171(2): 515 - 518. [Abstract] [Full Text] [PDF] T. Enzler, S. Gillessen, J. P. Manis, D. Ferguson, J. Fleming, F. W. Alt, M. Mihm, and G. Dranoff Deficiencies of GM-CSF and Interferon {gamma} Link Inflammation and Cancer J. Exp. Med., May 5, 2003; 197(9): 1213 - 1219. [Abstract] [Full Text] [PDF] Y. Hayakawa, J. M. Kelly, J. A. Westwood, P. K. Darcy, A. Diefenbach, D. Raulet, and M. J. Smyth Cutting Edge: Tumor Rejection Mediated by NKG2D Receptor-Ligand Interaction Is Dependent upon Perforin J. Immunol., November 15, 2002; 169(10): 5377 - 5381. [Abstract] [Full Text] [PDF] Y. Hayakawa, K. Takeda, H. Yagita, M. J. Smyth, L. Van Kaer, K. Okumura, and I. Saiki IFN-gamma -mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha -galactosylceramide Blood, August 13, 2002; 100(5): 1728 - 1733. [Abstract] [Full Text] [PDF] S. Nagakura, S. Ishihara, D. E. Dunn, J.-i. Nishimura, T. Kawaguchi, K. Horikawa, M. Hidaka, T. Kagimoto, N. Eto, H. Mitsuya, et al. Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro Blood, July 18, 2002; 100(3): 1031 - 1037. [Abstract] [Full Text] [PDF] S. E.A. Street, J. A. Trapani, D. MacGregor, and M. J. Smyth Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon {gamma} J. Exp. Med., July 1, 2002; 196(1): 129 - 134. [Abstract] [Full Text] [PDF] E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice J. Immunol., February 1, 2002; 168(3): 1356 - 1361. [Abstract] [Full Text] [PDF] K. Takeda, M. J. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagita, and K. Okumura Critical Role for Tumor Necrosis Factor-related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development J. Exp. Med., January 14, 2002; 195(2): 161 - 169. [Abstract] [Full Text] [PDF] M. J. Smyth, E. Cretney, K. Takeda, R. H. Wiltrout, L. M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon {gamma}-Dependent Natural Killer Cell Protection from Tumor Metastasis J. Exp. Med., March 19, 2001; 193(6): 661 - 670. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Street, S. E. A. Articles by Smyth, M. J. Search for Related Content PubMed PubMed Citation Articles by Street, S. E. A. Articles by Smyth, M. J. Related Collections Immunobiology Neoplasia Related Article in Blood Online Social Bookmarking                   What's this?

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020